Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

September 19, 2023

Rentschler Biopharma names new CEO, and first U.S. president for Milford

Photos | courtesy of Rentschler Biopharma, Inc. The Rentschler Biopharma facility in Milford is used to perform contract developing and manufacturing for other company's products, particularly pharmaceuticals.

German contract drug manufacturing company Rentschler Biopharma SE named Benedikt von Braunmühl as its new CEO and hired Tom Roberts as its first president of Milford-based Rentchler Biopharma Inc. and general manager U.S. 

Prior to joining Rentschler Biopharma on Tuesday, von Braunmühl served as CEO of HMNC Brain Health in Munich, Germany, where he transformed a research-focused organization to a clinical-stage biopharma company, according to a Tuesday press release from Rentschler. He replaced Frank Mathias in the role of CEO.

Photo | Courtesy of Rentschler
Rentschler Biopharma SE CEO Benedikt von Braunmuehl

Roberts joined the company in his newly-created role on Sept. 12 and oversees U.S. operation of the company, including its Milford facility where the company employs 228 people and is undergoing the largest expansion in its history.

“I am excited to join the Rentschler Biopharma team as the company looks to expand its U.S. business,” Roberts said in the press release. “I look forward to working closely with the entire team as we continue to build, always keeping in mind what our clients need to successfully bring life-saving treatments to patients.”  

He was previously at Texas-based Vitanova Biomedical, where he provided executive leadership, facilitated funding, and oversaw business and product development, regulatory compliance, manufacturing, and technology acquisition of a groundbreaking nanoparticle-based combination cancer therapeutic.

Photo | Courtesy of Rentschler Biopharma
Tom Roberts as President of Rentschler Biopharma Inc. and General Manager of U.S. Operations

“This is a critical time for our U.S. operations as we ramp up our state-of-the-art Rentschler Biopharma Manufacturing Center facility, the largest expansion in our company’s 150-year history,” Nikolaus Rentschler, chairman of the supervisory board, said in the press release. “Under Tom Robert’s leadership, we look forward to broadening our U.S. business and continuing to effectively serve our global clients and patients out of Milford.” 

Rentschler is a fifth-generation biopharmaceutical contract manufacturing company, based in Laupheim, Germany, roughly between Stuttgart and Munich. It has facilities in Milford and Stevenage, United Kingdom, employing approximately 1,300 worldwide. 

Sign up for Enews

WBJ Web Partners


Order a PDF